- Inhibitors
- Antibodies
- Compound Libraries
- New Products
- Contact Us
research use only
Cat.No.S1370
| Related Targets | Integrase Antibiotics Anti-infection Fungal Antiviral COVID-19 Parasite Reverse Transcriptase HIV HCV Protease |
|---|---|
| Other Bacterial Products | Berberine BTZ043 Racemate Teicoplanin Ornidazole Skatole Berberine Sulfate Pipemidic acid Ceftiofur PBTZ169 Aminothiazole |
|
In vitro |
Water : 5 mg/mL
DMSO
: Insoluble
Ethanol : Insoluble |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | 350.39 | Formula | C15H18N4O4S |
Storage (From the date of receipt) | |
|---|---|---|---|---|---|
| CAS No. | 120410-24-4 | Download SDF | Storage of Stock Solutions |
|
|
| Synonyms | L-627, LJC10627 | Smiles | CC1C2C(C(=O)N2C(=C1SC3CN4C=NC=[N+]4C3)C(=O)[O-])C(C)O | ||
| In vitro |
Biapenem has activity comparable to those of Imipenem and Meropenem against all groups of anaerobes with MICs for 90% of the strains tested of 0.06 to 2 mg/mL. This compound is more active than ampicillin-sulbactam, ticarcillin-clavulanate, piperacillin, cefoxitin, cefotaxime, and ceftriaxone. It is also active against all of the B. capillosus, Prevotella, Clostridium, and Eubacterium strains and anaerobic cocci tested. This agent shows broad antibacterial activity against both Gram-positive and Gram-negative clinical isolates. It is found to be approximately as active as imipenem, inhibiting 90% of isolates of most species at concentrations within one dilution of the MIC of imipenem for 90% of the isolates.
|
|---|---|
| In vivo |
Biapenem results in significantly fewer viable bacteria than in the lungs of control mice. This compound prevents the progression of lung inflammation, including alveolar neutrophil infiltration and hemorrhage. It significantly prolongs survival and reduces the number of viable bacteria in a murine model of VAP caused by P. aeruginosa.
|
References |
|
(data from https://clinicaltrials.gov, updated on 2024-05-22)
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT01772836 | Completed | Healthy Volunteers|Bacterial Infections |
Rempex Pharmaceuticals (a wholly owned subsidiary of The Medicines Company) |
March 2013 | Phase 1 |
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.